4.5 Article

Altered Distribution of RhoA in Alzheimer's Disease and A beta PP Overexpressing Mice

Journal

JOURNAL OF ALZHEIMERS DISEASE
Volume 19, Issue 1, Pages 37-56

Publisher

IOS PRESS
DOI: 10.3233/JAD-2010-1203

Keywords

Actin; cytoskeleton; microtubules; neurofibrillary tangles; Pick's disease; synaptic terminals; tau

Categories

Funding

  1. Marato-TV3 Foundation [061030]
  2. European Commission [LSHM-CT-2004-503039]
  3. Exgenesis Integrated Project [LSHM-CT-2004-005272]
  4. Spanish Secretary of Education and Science [SAF2005-00671, SAF 2008-00435]
  5. RETICS [RD07/0060/0002]

Ask authors/readers for more resources

RhoGTPases control cytoskeleton dynamics thereby modulating synaptic plasticity. Because Alzheimer's disease (AD) is characterized by synaptic dysfunction, we sought to determine whether the expression, activity, or localization of the GTPases RhoA, Rac1 and Cdc42, as well as p21-PAK, a downstream target of Rac1/Cdc42, were altered in 18-month-old A beta PP Tg2576 mice (Swedish mutation) or in brains from patients with AD and, for comparison in the case of RhoA, Pick's disease (PiD), a neurodegenerative disorder characterized by hyper-phosphorylated tau accumulation. Immunohistochemical analyses revealed a distinct localization of each RhoGTPase in synapses, dendrite shafts, neuronal bodies, or astrocytes. The association of RhoA with synapses and dendritic microtubules was confirmed by electron microscopy. In A beta PP mice, RhoA expression decreased in synapses and increased in dystrophic neurites, suggesting altered subcellular targeting of RhoA. In AD, RhoA immunostaining decreased in the neuropil and markedly increased in neurons, co-localizing with hyperphosphorylated tau inclusions, as though RhoA were sequestered by neurofibrillary tangles. Additionally, total RhoA protein was lower in the AD brain hippocampus, reflecting loss of the membrane bound, presumably active, GTPase. RhoA colocalized with hyperphosphorylated tau in PiD, again suggesting that altered subcellular targeting of RhoA is related to neurodegeneration. No major immunohistochemical changes were observed for Rac1, Cdc42, or p21-PAK, thus identifying RhoA among RhoGTPases as a possible therapeutic target in AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available